Thus, the present study aimed to determine the following: 1) whether VEGF is highly expressed in MDA-MB-468 cells, compared to MCF-7 and MDA-MB-231 cells; 2) whether sunitinib inhibits the proliferation, migration, apoptosis resistance of cultured MDA-MB-468 cells; 3) whether oral sunitinib treatment suppresses tumor angiogenesis and growth in the basal-like TNBC (MDA-MB-468) xenografts; 4) whether sunitinib increases the percentage of breast cancer stem cells in the xenografts; and 5) whether sunitinib increases the expression of Notch-1 in MDA-MB-468 cells. This evidence concerns the gene NOTCH1 and breast carcinoma.